Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis of an advanced, spreading, or inoperable solid tumour with specific genetic changes (called ERBB2-activating alterations, NRG1 gene fusions, or HER2 overexpression) detected in a blood or tumour test — this applies to Part A of the trial
- People who have a confirmed diagnosis of advanced, spreading, or inoperable non-small cell lung cancer (a type of lung cancer) with a specific genetic change called an ERBB2 mutation detected in a blood or tumour test — this applies to Part B of the trial
- People who have a confirmed diagnosis of advanced, spreading, or inoperable breast cancer with a specific ERBB2 genetic change or HER2 overexpression detected in a blood or tumour test — this applies to Part C of the trial
- People whose cancer can be measured on scans according to a standard set of medical guidelines (called RECIST v1.1)
- People who have a general health rating of 0 or 1 on a standard scale used by doctors (for Part A), or a rating of 0, 1, or 2 (for Parts B and C) — confirm exact details with the trial site
- People whose recent blood and chemistry test results fall within acceptable ranges as determined by the trial site
Who may not be able to join:
- People who have received certain chemotherapy, anti-cancer treatments, or radiation therapy within specific timeframes before the trial starts (confirm exact timeframes with the trial site)
- People who have had major surgery — such as brain or chest surgery — within 4 weeks before the trial starts
- People who have had focused radiation therapy to a small area (such as targeted brain or body radiation) within 2 weeks, or whole-brain radiation therapy within 4 weeks, before the trial starts
- People who have a significant heart condition
- People whose side effects from previous cancer treatments have not settled back to a mild level or to their baseline health before the trial starts
- People who require corticosteroid medications (a type of anti-inflammatory drug) to manage neurological symptoms, depending on which part of the trial is being considered (confirm specific restrictions with the trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 617-945-5576
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Part A]; Overall Response Rate [Part B and Part C]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.